"Azetidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D001384
|
MeSH Number(s) |
D03.383.082.301
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azetidines".
Below are MeSH descriptors whose meaning is more specific than "Azetidines".
This graph shows the total number of publications written about "Azetidines" by people in this website by year, and whether "Azetidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2003 | 2 | 0 | 2 |
2004 | 4 | 1 | 5 |
2005 | 1 | 0 | 1 |
2006 | 5 | 0 | 5 |
2007 | 4 | 1 | 5 |
2008 | 2 | 0 | 2 |
2009 | 4 | 2 | 6 |
2011 | 3 | 1 | 4 |
2012 | 1 | 1 | 2 |
2013 | 1 | 3 | 4 |
2014 | 0 | 1 | 1 |
2015 | 1 | 1 | 2 |
2016 | 1 | 2 | 3 |
2019 | 1 | 4 | 5 |
2020 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2022 | 0 | 2 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azetidines" by people in Profiles.
-
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). J Immunother Cancer. 2024 Feb 05; 12(2).
-
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2022 09; 23(9):1145-1155.
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
-
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series. Neurol Neuroimmunol Neuroinflamm. 2021 11; 9(1).
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
-
Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
-
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
-
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020 03; 105(3):697-707.
-
Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury. Cell Mol Gastroenterol Hepatol. 2019; 8(3):379-405.
-
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.